Drug intelligence / Profile preview

TNK05

Development stage: Preclinical
Lead developer: Nanjing Tongnuokang Pharmaceutical Technology
Modality: Small Molecules

Overview

TNK05 is a preclinical-stage small molecule developed by SynoCare for the treatment of various inflammatory and autoimmune conditions, including inflammatory enteritis, Crohn's disease, rheumatoid arthritis, and allergic rhinitis. The drug utilizes a novel RNA-targeting small-molecule strategy. While the specific RNA target (referred to as TNK05XX) and the precise mechanism of action remain undisclosed by the sponsor, the program aims to modulate disease-relevant pathways at the transcript level.

Other names: TNK05TNK-05TNK 05

Beyond the preview

Go deeper on TNK05.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TNK05.

Explore the full profile